Program
HRS-5965
A development code. Also written as “HRS-5965 Capsules”, “HRS-5965 capsule” and “HRS-5965 tablets”.
In Jiangsu HengRui Medicine's pipeline, Factor B
. Its studies are mostly in Glomerulonephritis, IGA · Hemoglobinuria, Paroxysmal · Anemia, Hemolytic · Glomerulonephritis, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 143 open or running | phase 3since Sep 10, 2024 | Aug 16, 2022 | Oct 2027phase 3 · NCT07014826 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-5965
, phase 4, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 16, 2022First study: phase 1 study in GlomerulonephritisFirst studyNCT05505955 · 83 enrolled · China
- Sep 5, 2023Phase 2 study in Hemoglobinuria, ParoxysmalNCT06051357 · 26 enrolled · China
- Nov 14, 2023Phase 2 study in Glomerulonephritis, IGANCT06137768 · 123 enrolled · China
- Jan 22, 2024Phase 2 study in Hemoglobinuria, ParoxysmalNCT06238544 · 132 enrolled · China
- Jun 23, 2024Phase 1 study in Paroxysmal Nocturnal Hemoglobinuria,IgA NephropathyNCT06490991 · 16 enrolled · China
- Aug 20, 2024Phase 1 study in Complement Mediated Primary or Secondary Glomerular DiseasesNCT06567392 · 6 enrolled · China
- Sep 10, 2024Phase 3 study in Hemoglobinuria, ParoxysmalNCT06593938 · 76 enrolled · China
- Nov 1, 20242 phase 1 studiesNCT06684041, NCT06674915
- Nov 28, 2024Phase 3 study in Hemoglobinuria, ParoxysmalNCT06715943 · 39 enrolled · China
- May 22, 2025Phase 3 study in Glomerulonephritis, IGANCT07014826 · 378 planned · China
- Jun 16, 20252 phase 1 studiesNCT07035665, NCT07040787
- May 6, 2026Phase 2 study in Glomerulonephritis, IGANCT07582133 · 380 planned · China
Ahead
- Oct 2027Primary completion: phase 3 study in Glomerulonephritis, IGANCT07014826
- Dec 2027Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT06238544
- Jul 2029Primary completion: phase 2 study in Glomerulonephritis, IGANCT07582133
TargetBeta
“Factor B”the company's pipeline, read by Claude · source
Other programs on CFB
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07582133Glomerulonephritis, IGA · China | 2 | Recruiting | Jul 2029 | 380 |
| NCT07040787Anemia, Hemolytic · China | 1 | Completed | Aug 17, 2025 | 36 |
| NCT07035665Glomerulonephritis, IGA · China | 1 | Completed | Jul 22, 2025 | 16 |
| NCT07014826Glomerulonephritis, IGA · China | 3 | Recruiting | Oct 2027 | 378 |
| NCT06715943Hemoglobinuria, Paroxysmal · China | 3 | Completed | Jan 6, 2026 | 39 |
| NCT06674915Complement Mediated Primary or Secondary Glomerular Diseases · China | 1 | Completed | Jan 16, 2026 | 24 |
| NCT06684041Anemia, Hemolytic · China | 1 | Completed | Apr 7, 2025 | 32 |
| NCT06593938Hemoglobinuria, Paroxysmal · China | 3 | Completed | Jul 31, 2025 | 76 |
| NCT06567392Complement Mediated Primary or Secondary Glomerular Diseases · China | 1 | Completed | Oct 8, 2024 | 6 |
| NCT06490991Paroxysmal Nocturnal Hemoglobinuria,IgA Nephropathy · China | 1 | Completed | Aug 6, 2024 | 16 |
| NCT06238544Hemoglobinuria, Paroxysmal · China | 2 | Active, not recruiting | Dec 2027 | 132 |
| NCT06137768Glomerulonephritis, IGA · China | 2 | Completed | Oct 17, 2025 | 123 |
| NCT06051357Hemoglobinuria, Paroxysmal · China | 2 | Completed | Mar 25, 2024 | 26 |
| NCT05505955Glomerulonephritis · China | 1 | Completed | Nov 3, 2023 | 83 |
How it is read
Names in the registry
- “HRS-5965 Capsules”, 4 entries
- “HRS-5965”, 3 entries
- “HRS-5965 capsule”, 3 entries
- “HRS-5965 tablets”, 2 entries
- “HRS-5965 capsules”, 1 entry
Codes read as this program: HRS5965.
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 5 studies
- Hemoglobinuria, Paroxysmal, 4 studies
- Anemia, Hemolytic, 2 studies
- Glomerulonephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.